Background： We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma（PAC）.Methods： A total of 563 patients who were curatively resected for PAC were retrospectively ana...Background： We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma（PAC）.Methods： A total of 563 patients who were curatively resected for PAC were retrospectively analyzed between 2003 and 2013.Results： Of 563 patients, 472 received adjuvant chemotherapy（CT） alone, chemoradiotherapy（CRT） alone, and chemoradiotherapy plus chemotherapy（CRT-CT） were analyzed. Of the 472 patients, 231 were given CRT-CT, 26 were given CRT, and 215 were given CT. The median recurrence-free survival（RFS） and overall survival（OS） were 12 and 19 months, respectively. When CT and CRT-CT groups were compared, there was no significant difference with respect to both RFS and OS, and also there was no difference in RFS and OS among CRT-CT, CT and CRT groups. To further investigate the impact of radiation on subgroups, patients were stratified according to lymph node status and resection margins. In node-positive patients, both RFS and OS were significantly longer in CRT-CT than CT. In contrast, there was no significant differencebetween groups when patients with node-negative disease or patients with or without positive surgical margins were considered.Conclusions： Addition of radiation to CT has a survival benefit in patients with node-positive disease following pancreatic resection.展开更多
Background In recent years, increasing numbers of patients are accepting neoadjuvant chemotherapy before their operation in order to get a better prognosis. But chemotherapy has many side-effects. We have observed tha...Background In recent years, increasing numbers of patients are accepting neoadjuvant chemotherapy before their operation in order to get a better prognosis. But chemotherapy has many side-effects. We have observed that patients who accepted neoadjuvant chemotherapy are more sensitive to anesthetics. The aim of this study was to determine the median effective dose （EC50） of intravenous anesthetics for neoadjuvant chemotherapy patients to lose consciousness during target-controlled infusion.Methods Two hundred and forty breast cancer patients undergoing elective operations were assigned to six groups according to treatment received before their operation and the use of intravenous anesthetics during anesthesia;non-adjuvant chemotherapy＋propofol group （group NP, n=40）, Taxol＋propofol group （group TP, n=40）,adriamycine＋cyclophosphamide＋5-Fu＋propofol group （group CP, n=40）, non-adjuvant chemotherapy＋etomidate group （group NE, n=40）, taxol＋etomidate group （group TE, n=40）, adriamycine＋cyclophosphamide＋5-Fu＋etomidate group （group CE, n=40）. We set the beginning effect-site concentration （Ce） of propofol as 3.0 μg/ml and etomidate as 0.2μg/ml. The concentration was increased by steps until the patient was asleep, （OAAS class Ⅰ-Ⅱ）, then gave fentanyl 3μg/kg and rocuronium 0.6 mg/kg and intubated three minutes later. The patients＇ age, height, and weight were recorded.BIS was recorded before induction, at the initial effect-site concentration and at loss of consciousness. The effect-site concentration was recorded when patient lost consciousness.Results There were no significant differences between groups in general conditions before treatment; such as BIS of consciousness, age, sex and body mass index. The EC50 of propofol in the NP, TP and CP groups was 4.11 μg/ml （95%CI： 3.96-4.26）, 2.94 μg/ml （95% CI： 3.36-3.47） and 2.91 μg/ml （95% CI： 3.35-3.86）, respectively. The EC50 of etomidate in the NE, TE and CE groups was 0.61 μg/ml （95% C展开更多
目的:评价进展期胃癌病人术后应用辅助化疗的疗效。方法:检索Entrez PubMed数据库、EMBASE数据库、Ovid数据库中的循证医学数据库、ISI Web of Knowledge数据库和中国生物医学文献数据库中有关胃癌术后辅助化疗疗效的随机对照临床试验文...目的:评价进展期胃癌病人术后应用辅助化疗的疗效。方法:检索Entrez PubMed数据库、EMBASE数据库、Ovid数据库中的循证医学数据库、ISI Web of Knowledge数据库和中国生物医学文献数据库中有关胃癌术后辅助化疗疗效的随机对照临床试验文献,分析病人术后总生存率的风险比率(hazard ratio,HR)及其95%可信区间(confidence interval,CI)。结果:1998年1月至2009年12月间共检索到13篇文献(4067例病例),Jadad评分均为3分。发现手术合并化疗组相对于单独手术组病人的术后生存率的HR(95%CI)为0.79(0.72,0.86),亚组分析发现术后辅助化疗的有效性不受肿瘤淋巴结转移情况、淋巴结清扫手术类型、人种及化疗药物给药途径等因素的影响。源于日本之临床试验报道的术后生存率明显高于西方国家。结论:术后辅助化疗能使进展期胃癌病人获益。标准的D2淋巴结清扫手术联合术后口服氟尿嘧啶化疗是这类病人的最佳选择之一。展开更多
AIM To develop a leptin peptide receptor antagonist linked to nanoparticles and determine its effect on viability of breast cancer cells.METHODS The leptin antagonist, LPrA2, was coupled via EDAC [1-Ethyl-3-(3-dimethy...AIM To develop a leptin peptide receptor antagonist linked to nanoparticles and determine its effect on viability of breast cancer cells.METHODS The leptin antagonist, LPrA2, was coupled via EDAC [1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide] to iron oxide nanoparticles(IONP-LPrA2) to increase its efficacy.IONP-LPrA2 conjugation was confirmed by Western blot and nanoparticle tracking analysis.Human triple negative breast cancer(TNBC) MDA-MB-231, HCC1806 and estrogen receptor positive(ER+) MCF-7 cells were analyzed for the expression of the leptin receptor, Ob-R.The effects of leptin and antagonist on levels of leptin-induced STAT3 phosphorylation and cyclin D1, cell cycle progression, cell proliferation, and tumorsphere formation in breast cancer cells were determined.Doses of the chemotherapeutics [cisplatin(Cis), cyclophosphamide(CTX), doxorubicin(Dox) and paclitaxel(PTX)] to effectively reduce cell viability were calculated.The effects of combination treatments of IONP-LPrA2 and chemotherapeutics on cell viability were determined.RESULTS Western blot analysis of coupling reaction products identified IONP-LPrA2 at approximately 100 kD.IONPLPrA2 significantly decreased leptin-induced p STAT3 levels in HCC1806 cells and drastically decreased cyclin D1 levels in all cell lines.IONP-LPrA2 significantly reduced leptin-induced S phase progression and cell proliferation in all breast cancer cell lines and the formation of tumorspheres in MDA-MB-231 cells.Also, IONP-LPrA2 showed an additive effect on the reduction of breast cancer cell survival with chemotherapeutics.Cis plus IONP-LPrA2 produced a significant reduction in the survival of MDA-MB-231 and HCC1806 cells.CTX plus IONP-LPrA2 caused a significant decrease in the survival of MDA-MB-231 cells.Dox plus IONP-LPrA2 caused a marked reduction in the survival of HCC1806 cells.Although, PTX plus IONP-LPrA2 did not have a major effect on the viability of the breast cancer cells when compared to PTX alone.CONCLUSION Present data indicate that IONP-LPrA2 may be a useful展开更多
进展期贲门癌的治疗以手术为首选方法,治疗效果较差.即使施行根治术也往往不能达到根治效果,大多数患者死于腹腔复发和转移.常见的复发转移部位是手术野区域、淋巴结、腹膜表面及盆腔脏器.临床上常用的辅助治疗方法如静脉化疗、腹腔内...进展期贲门癌的治疗以手术为首选方法,治疗效果较差.即使施行根治术也往往不能达到根治效果,大多数患者死于腹腔复发和转移.常见的复发转移部位是手术野区域、淋巴结、腹膜表面及盆腔脏器.临床上常用的辅助治疗方法如静脉化疗、腹腔内化疗药物、蒸馏水浸泡等效果并不理想.近年来,用内源放射性物质诊断、治疗肿瘤的报道日趋增多.朱瑞森等用^(131)I-MIBC 对58例恶性嗜铬细胞瘤临床治疗的疗效副反应进行探讨,匡安仁等对放射性碘对于肝癌的趋瘤性进行了研究,孙爱君等对^(18)F-FDG PET 头颈部癌治疗后复发中的应用进行了研究,兰青等用^(35)S 标记 SZ39导向治疗胶质瘤、李广宙 et al 用^(32)p展开更多
文摘Background： We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma（PAC）.Methods： A total of 563 patients who were curatively resected for PAC were retrospectively analyzed between 2003 and 2013.Results： Of 563 patients, 472 received adjuvant chemotherapy（CT） alone, chemoradiotherapy（CRT） alone, and chemoradiotherapy plus chemotherapy（CRT-CT） were analyzed. Of the 472 patients, 231 were given CRT-CT, 26 were given CRT, and 215 were given CT. The median recurrence-free survival（RFS） and overall survival（OS） were 12 and 19 months, respectively. When CT and CRT-CT groups were compared, there was no significant difference with respect to both RFS and OS, and also there was no difference in RFS and OS among CRT-CT, CT and CRT groups. To further investigate the impact of radiation on subgroups, patients were stratified according to lymph node status and resection margins. In node-positive patients, both RFS and OS were significantly longer in CRT-CT than CT. In contrast, there was no significant differencebetween groups when patients with node-negative disease or patients with or without positive surgical margins were considered.Conclusions： Addition of radiation to CT has a survival benefit in patients with node-positive disease following pancreatic resection.
文摘Background In recent years, increasing numbers of patients are accepting neoadjuvant chemotherapy before their operation in order to get a better prognosis. But chemotherapy has many side-effects. We have observed that patients who accepted neoadjuvant chemotherapy are more sensitive to anesthetics. The aim of this study was to determine the median effective dose （EC50） of intravenous anesthetics for neoadjuvant chemotherapy patients to lose consciousness during target-controlled infusion.Methods Two hundred and forty breast cancer patients undergoing elective operations were assigned to six groups according to treatment received before their operation and the use of intravenous anesthetics during anesthesia;non-adjuvant chemotherapy＋propofol group （group NP, n=40）, Taxol＋propofol group （group TP, n=40）,adriamycine＋cyclophosphamide＋5-Fu＋propofol group （group CP, n=40）, non-adjuvant chemotherapy＋etomidate group （group NE, n=40）, taxol＋etomidate group （group TE, n=40）, adriamycine＋cyclophosphamide＋5-Fu＋etomidate group （group CE, n=40）. We set the beginning effect-site concentration （Ce） of propofol as 3.0 μg/ml and etomidate as 0.2μg/ml. The concentration was increased by steps until the patient was asleep, （OAAS class Ⅰ-Ⅱ）, then gave fentanyl 3μg/kg and rocuronium 0.6 mg/kg and intubated three minutes later. The patients＇ age, height, and weight were recorded.BIS was recorded before induction, at the initial effect-site concentration and at loss of consciousness. The effect-site concentration was recorded when patient lost consciousness.Results There were no significant differences between groups in general conditions before treatment; such as BIS of consciousness, age, sex and body mass index. The EC50 of propofol in the NP, TP and CP groups was 4.11 μg/ml （95%CI： 3.96-4.26）, 2.94 μg/ml （95% CI： 3.36-3.47） and 2.91 μg/ml （95% CI： 3.35-3.86）, respectively. The EC50 of etomidate in the NE, TE and CE groups was 0.61 μg/ml （95% C
文摘目的:评价进展期胃癌病人术后应用辅助化疗的疗效。方法:检索Entrez PubMed数据库、EMBASE数据库、Ovid数据库中的循证医学数据库、ISI Web of Knowledge数据库和中国生物医学文献数据库中有关胃癌术后辅助化疗疗效的随机对照临床试验文献,分析病人术后总生存率的风险比率(hazard ratio,HR)及其95%可信区间(confidence interval,CI)。结果:1998年1月至2009年12月间共检索到13篇文献(4067例病例),Jadad评分均为3分。发现手术合并化疗组相对于单独手术组病人的术后生存率的HR(95%CI)为0.79(0.72,0.86),亚组分析发现术后辅助化疗的有效性不受肿瘤淋巴结转移情况、淋巴结清扫手术类型、人种及化疗药物给药途径等因素的影响。源于日本之临床试验报道的术后生存率明显高于西方国家。结论:术后辅助化疗能使进展期胃癌病人获益。标准的D2淋巴结清扫手术联合术后口服氟尿嘧啶化疗是这类病人的最佳选择之一。
基金The National Cancer Institute at the National Institutes of Health(1R41 CA183399-01A1 to Ruben R Gonzalez-Perez5U54 CA118638,S21 MD000101,5G12 MD0076021,G12 RR026250-03,NIH RR03034 and 1C06 RR18386 to Morehouse School of Medicine)+1 种基金the National Institute of General Medical Sciences,Research Initiative for Scientific Enhancement Program(RISE 5R25 GM058268 to Tia Harmon)the Congressionally Directed Medical Research Programs-Department of Defense(CDMRP DOD W81XWH-13-1-0382 to Ruben R Gonzalez-Perez)
文摘AIM To develop a leptin peptide receptor antagonist linked to nanoparticles and determine its effect on viability of breast cancer cells.METHODS The leptin antagonist, LPrA2, was coupled via EDAC [1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide] to iron oxide nanoparticles(IONP-LPrA2) to increase its efficacy.IONP-LPrA2 conjugation was confirmed by Western blot and nanoparticle tracking analysis.Human triple negative breast cancer(TNBC) MDA-MB-231, HCC1806 and estrogen receptor positive(ER+) MCF-7 cells were analyzed for the expression of the leptin receptor, Ob-R.The effects of leptin and antagonist on levels of leptin-induced STAT3 phosphorylation and cyclin D1, cell cycle progression, cell proliferation, and tumorsphere formation in breast cancer cells were determined.Doses of the chemotherapeutics [cisplatin(Cis), cyclophosphamide(CTX), doxorubicin(Dox) and paclitaxel(PTX)] to effectively reduce cell viability were calculated.The effects of combination treatments of IONP-LPrA2 and chemotherapeutics on cell viability were determined.RESULTS Western blot analysis of coupling reaction products identified IONP-LPrA2 at approximately 100 kD.IONPLPrA2 significantly decreased leptin-induced p STAT3 levels in HCC1806 cells and drastically decreased cyclin D1 levels in all cell lines.IONP-LPrA2 significantly reduced leptin-induced S phase progression and cell proliferation in all breast cancer cell lines and the formation of tumorspheres in MDA-MB-231 cells.Also, IONP-LPrA2 showed an additive effect on the reduction of breast cancer cell survival with chemotherapeutics.Cis plus IONP-LPrA2 produced a significant reduction in the survival of MDA-MB-231 and HCC1806 cells.CTX plus IONP-LPrA2 caused a significant decrease in the survival of MDA-MB-231 cells.Dox plus IONP-LPrA2 caused a marked reduction in the survival of HCC1806 cells.Although, PTX plus IONP-LPrA2 did not have a major effect on the viability of the breast cancer cells when compared to PTX alone.CONCLUSION Present data indicate that IONP-LPrA2 may be a useful
文摘进展期贲门癌的治疗以手术为首选方法,治疗效果较差.即使施行根治术也往往不能达到根治效果,大多数患者死于腹腔复发和转移.常见的复发转移部位是手术野区域、淋巴结、腹膜表面及盆腔脏器.临床上常用的辅助治疗方法如静脉化疗、腹腔内化疗药物、蒸馏水浸泡等效果并不理想.近年来,用内源放射性物质诊断、治疗肿瘤的报道日趋增多.朱瑞森等用^(131)I-MIBC 对58例恶性嗜铬细胞瘤临床治疗的疗效副反应进行探讨,匡安仁等对放射性碘对于肝癌的趋瘤性进行了研究,孙爱君等对^(18)F-FDG PET 头颈部癌治疗后复发中的应用进行了研究,兰青等用^(35)S 标记 SZ39导向治疗胶质瘤、李广宙 et al 用^(32)p
